spacer
home > > winter 2020 > a scalable solution
PUBLICATIONS


A Scalable Solution




A key issue for small and medium-sized enterprises (SMEs) in life science is the optimal utilisation of their limited resources for moving their product pipeline through clinical development, and launching and marketing their approved products. This is further heightened as both clinical trials and post-marketing activities continue to grow in complexity and scope due to stringent regulatory pressures, patient involvement, and globalisation. Regardless, companies face overwhelming pressure to get their product to market as quickly as possible.

Clinical trials are typically outsourced end-to-end to full-service CROs. SMEs may select CROs for their niche patient recruitment capabilities in certain geographies and therapeutic areas/indications. As a result, some CROs may not always have the required level of expertise and experience in other aspects of clinical trials, such as data management, statistical design and analysis, medical writing, and regulatory submissions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Susan Najjar at Covance has over 25 years of industry experience with several years in senior leadership and consulting positions. Susan oversaw global marketing activities for Thermo Fisher Scientificís informatics division, developing growth strategies and implementing innovative marketing programmes. Prior to Thermo, she was accountable for establishing the Gillette Companyís North American Blades and Razors forecasting and planning, executing software product launches at Sun Microsystems, and consulting senior pharma executive teams at Deloitte & Touche. Susan has an MS in Biochemical Engineering from Tufts University, US, and an MBA from MIT Sloan, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Patients treated with Lynparza and bevacizumab lived without disease progression for a median of 37.2 months vs. 17.7 months with bevacizumab alone One in two women with advanced ovarian cancer has an HRD-positive tumour
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement